Document:

<PAGE>

                             FIRST AMENDMENT TO THE
                                ROYALTY AGREEMENT

                  This First Amendment, dated as of April 20, 2001 (this
"AMENDMENT"), to the Royalty Agreement, dated as of December 26, 2000 (the
"ROYALTY AGREEMENT") by and between Cytomedix, Inc., a Delaware corporation
("CYTOMEDIX"), and Curative Health Services, Inc., a Minnesota corporation
("CURATIVE"). Terms used herein but not defined shall have the meanings
ascribed in the Royalty Agreement.

                                    RECITALS

                  WHEREAS, the parties entered into the Royalty Agreement
pursuant to the terms and conditions of an Amended and Restated Asset
Purchase Agreement, effective as of October 12, 2000 (the "ASSET PURCHASE
AGREEMENT"), pursuant to which Cytomedix purchased certain assets of Curative
and its affiliates as set forth therein, including the Patents;

                  WHEREAS, Cytomedix entered into a license agreement,
effective March 19, 2001, between Cytomedix and DePuy AeroMed, Inc. ("DEPUY")
(the "LICENSE AGREEMENT"), and under the Royalty Agreement, Cytomedix is
required to pay Curative royalties on the Net Sales Amount of the Future
Products sold thereunder; and

                  WHEREAS, Cytomedix and Curative are parties to a Consent,
Payoff, Conversion and Exchange Agreement dated the date hereof, under which
Cytomedix and Curative have agreed to amend the Royalty Agreement as set
forth in this Amendment as partial consideration for the transactions
contemplated by the Consent, Payoff, Conversion and Exchange Agreement.

                  NOW, THEREFORE, for and in consideration of the premises
and the mutual covenants contained herein, and for other good and valuable
consideration, the receipt, adequacy and legal sufficiency of which are
hereby acknowledged, the parties do hereby agree as follows:

                  1.       The definition of "FUTURE PRODUCTS" in Article I
of the Royalty Agreement shall be replaced, to read in its entirety as
follows:

                  "FUTURE PRODUCTS" - ANY PRODUCTS WHICH EMBODY ANY OF THE
PATENTS OR ARE COVERED BY ANY CLAIM OF THE PATENTS.

                  2.       Section 2.2 of the Royalty Agreement shall be
replaced, to read in its entirety as follows:

                  "SECTION 2.2  PAYMENT OF ROYALTY.

                  (a)      EXCEPT AS SET FORTH IN PARAGRAPH (b) BELOW,
CYTOMEDIX SHALL PAY THE ROYALTY QUARTERLY. WITHIN FORTY-FIVE (45) DAYS AFTER
THE END OF EACH CALENDAR QUARTER, CYTOMEDIX SHALL (i) PAY CURATIVE THE AMOUNT
OF THE ROYALTY OWED BY CYTOMEDIX FOR SUCH CALENDAR QUARTER, AND (ii) PROVIDE
CURATIVE WITH A WRITTEN REPORT SETTING FORTH THE NET SALES AMOUNT WITH
RESPECT TO PROCUREN AND THE FUTURE PRODUCTS FOR THE APPLICABLE QUARTER, AND
THE COMPUTATION OF THE PROCUREN ROYALTY AND THE FUTURE PRODUCTS ROYALTY WITH
RESPECT THERETO FOR THE APPLICABLE QUARTER. THE ROYALTY SHALL BE PAYABLE IN
CURRENCY OF THE UNITED STATES OF AMERICA REGARDLESS OF THE COUNTRY WHERE
EARNED AND SHALL BE PAID OR DEPOSITED AS DESIGNATED IN WRITING BY CURATIVE.
THE EXCHANGE RATE USED TO CALCULATE THE ROYALTY SHALL BE THE SAME RATE
SPECIFIED UNDER FINANCIAL ACCOUNTING STANDARDS BOARD STATEMENT 52, OR ITS
SUCCESSOR, USED TO TRANSLATE THE FINANCIAL RESULTS OF CYTOMEDIX OR ITS
AFFILIATES FOR PUBLIC REPORTING. IF THE ROYALTY FOR THE

<PAGE>

PREVIOUS CALENDAR QUARTER REMAINS UNPAID WITHIN FORTY-FIVE (45) DAYS AFTER
THE END OF SUCH CALENDAR QUARTER, INTEREST SHALL ACCRUE ON SUCH UNPAID AMOUNT
AT THE LOWER OF (i) FIFTEEN PERCENT (15%) PER ANNUM, OR (ii) THE HIGHEST RATE
PERMITTED BY LAW, UNTIL PAID.

                  (b)      EACH OF CURATIVE AND CYTOMEDIX SHALL, AND
CYTOMEDIX SHALL USE ITS BEST EFFORTS TO CAUSE DEPUY TO, ENTER INTO AN
AGREEMENT SUBSTANTIALLY IN THE FORM ATTACHED HERETO AS EXHIBIT A, PURSUANT TO
WHICH APPROXIMATELY 92.3 PERCENT (92.3%) OF THE ROYALTIES PAYABLE TO
CYTOMEDIX UNDER THE LICENSE AGREEMENT SHALL BE PAID DIRECTLY TO CURATIVE AS
FOLLOWS:

                  (i)      SIX PERCENT (6%) OF ANY AND ALL NET SALES MADE BY
SUBLICENSORS OF PRODUCTS (AS DEFINED IN THE LICENSE AGREEMENT) SHALL BE MADE
DIRECTLY TO CURATIVE, PAYABLE ON A QUARTERLY BASIS BY FEDERAL FUNDS WIRE, TO
AN ACCOUNT SPECIFIED BY CURATIVE; AND

                  (ii)     ONE-HALF PERCENT (0.5%) OF ANY AND ALL NET SALES
MADE BY SUBLICENSORS OF PRODUCTS (AS DEFINED IN THE LICENSE AGREEMENT)SHALL
BE MADE TO CYTOMEDIX.

                  (c)      CYTOMEDIX SHALL, AND USE ITS BEST EFFORTS TO CAUSE
ANY PARTY TO AN ADDITIONAL LICENSE AGREEMENT (AS DEFINED IN SECTION 2.3) TO,
ENTER INTO AN AGREEMENT, PURSUANT TO WHICH SUCH PARTY WILL MAKE ANY ROYALTY,
UPFRONT OR MILESTONE PAYMENTS DIRECTLY TO CURATIVE THAT ARE DUE TO CURATIVE
AS SET FORTH HEREIN AND IN THE ROYALTY AGREEMENT."

                  3.       Section 2.3 of the Royalty Agreement shall be
replaced, to read in its entirety as follows:

                  "SECTION 2.3 OTHER PAYMENTS. CYTOMEDIX SHALL PAY CURATIVE
(i) THIRTY PERCENT (30 %) OF THE AGGREGATE PROCEEDS, SETTLEMENT AMOUNT OR
OTHER SIMILAR PAYMENT RECEIVED BY CYTOMEDIX (NET OF EXPENSES) IN CONNECTION
WITH A CLAIM BROUGHT BY CYTOMEDIX AGAINST A THIRD PARTY RELATING TO
INFRINGEMENT OR MISAPPROPRIATION OF THE PATENTS; AND (ii) TWENTY PERCENT
(20%) OF THE AGGREGATE AMOUNT RECEIVED BY CYTOMEDIX IN CONNECTION WITH
UPFRONT, MILESTONE AND/OR OTHER SIMILAR PAYMENTS RELATING TO THE PATENTS ((i)
AND (ii) ARE COLLECTIVELY REFERRED TO HEREIN AS THE "NON-ROYALTY PAYMENTS").
CYTOMEDIX SHALL IMMEDIATELY, BUT IN NO EVENT LATER THAN 3 BUSINESS DAYS,
NOTIFY CURATIVE OF THE CONSUMMATION OF ANY AGREEMENT WITH ANY THIRD PARTY
RELATING TO THE RIGHT TO PRACTICE OR UTILIZE ANY OF THE PATENTS (EACH, AN
"ADDITIONAL LICENSE AGREEMENT"), AND PROVIDE CURATIVE WITH A COPY OF SUCH
ADDITIONAL LICENSE AGREEMENT. EXCEPT AS EXPRESSLY PROVIDED HEREIN, CURATIVE
IS NOT ENTITLED TO ANY OTHER COMPENSATION FROM CYTOMEDIX OR ANY OTHER THIRD
PARTY IN CONNECTION WITH THE SALE OF PROCUREN AND THE FUTURE PRODUCTS AND
SHALL RECEIVE NO ROYALTY ON SALES OF ANY OTHER PRODUCT OF CYTOMEDIX."

                  4.       Section 6.1 of the Royalty Agreement shall be
replaced, to read in its entirety as follows:

                  "SECTION 6.1 SECURITY INTEREST. SUBJECT TO THE APPLICABLE
TERMS AND CONDITIONS OF THIS AGREEMENT, CYTOMEDIX HEREBY ASSIGNS AND GRANTS
TO CURATIVE A SECURITY INTEREST (THE "SECURITY INTEREST") IN AND A LIEN ON
THE PATENTS, INCLUDING (a) ALL RIGHTS TO PAYMENT AND PROCEEDS FROM SUCH
PATENTS AND (b) THE LICENSE AGREEMENT, ANY ADDITIONAL LICENSE AGREEMENT, AND
ALL PAYMENTS AND PROCEEDS THEREFROM (COLLECTIVELY, THE "COLLATERAL") TO
SECURE THE PAYMENT AND THE PERFORMANCE OF THE FOLLOWING OBLIGATIONS
(COLLECTIVELY, THE "OBLIGATIONS"):

                  (i)      THE PAYMENT OF THE ROYALTY AND THE NON-ROYALTY
PAYMENTS; AND

                  (ii)     ALL REASONABLE COSTS INCURRED BY CURATIVE TO
OBTAIN, PRESERVE, PERFECT AND ENFORCE THE PROVISIONS OF THIS ARTICLE VI AND
THE SECURITY INTEREST CREATED HEREBY, COLLECT THE ROYALTY AND

                                       2

<PAGE>

MAINTAIN AND PRESERVE THE COLLATERAL, INCLUDING BUT NOT LIMITED TO TAXES,
ASSESSMENTS, INSURANCE PREMIUMS, REPAIRS, REASONABLE ATTORNEY'S FEES AND
LEGAL EXPENSES, AND EXPENSES OF SALE."

                  5.       The last two sentences of Section 6.5 of the
Royalty Agreement shall be deleted and replaced, to read as follows:

                  "CURATIVE MAY ELECT TO EXERCISE ITS RIGHTS TO TAKE
POSSESSION AND RETAIN THE COLLATERAL IN SATISFACTION OF THE OBLIGATIONS."

                  6.       This Amendment shall not be deemed or construed
to: (i) constitute a waiver of any default by Cytomedix of any of its
obligations under the Royalty Agreement, or (ii) prejudice any right, power
or remedy which Curative may now have or have in the future under or in
connection with Cytomedix's breach of or default under the Royalty Agreement.

                                       3

<PAGE>

          [signature page to First Amendment to the Royalty Agreement]

                  IN WITNESS WHEREOF, the parties have executed this
Agreement as of the date first written above.

                          CYTOMEDIX:
                          CYTOMEDIX, INC.

                          By:   /s/ James A. Cour
                                ----------------------------------------------
                          Name: James A. Cour
                                ----------------------------------------------
                          Its:  Chief Executive Officer
                                ----------------------------------------------

                          CURATIVE:
                          CURATIVE HEALTH SERVICES, INC.

                          By:   /s/ William C. Tella
                                ----------------------------------------------
                          Name: William C. Tella
                                ----------------------------------------------
                          Its:  Senior Vice President for Business Development
                                ----------------------------------------------

                                     4

<PAGE>

                                    EXHIBIT A

                                    AGREEMENT

         This agreement ("Agreement"), dated as of April __, 2001, is made by
and among Curative Health Services, Inc., a Minnesota corporation
("Curative"), Cytomedix, Inc., a Delaware corporation ("Cytomedix") and DePuy
AcroMed, Inc., an Ohio corporation ("DePuy"). Terms used herein but not
defined shall have the meanings set forth in the License Agreement (as
defined below).

         WHEREAS, pursuant to a license agreement, effective March 19, 2001,
between Cytomedix and DePuy (the "License Agreement"), DePuy holds an
exclusive license relating to the Patents and DePuy has agreed to pay
Cytomedix a royalty six and one-half percent (6.5%) of the net sales made by
sublicensors of the Products;

         WHEREAS, Curative and Cytomedix are parties to that certain royalty
agreement, dated as of December 26, 2000 (the "Royalty Agreement"), pursuant
to which Cytomedix must pay Curative royalties on the sale of products
derived from the Patents, more specifically described therein; and

         WHEREAS, to secure the royalty payment obligations of Cytomedix,
Curative holds a security interest in the Patents, the proceeds therefrom and
the License Agreement.

         NOW, THEREFORE, for and in consideration of the premises and the
mutual covenants contained herein, and for other good and valuable
consideration, the receipt, adequacy and legal sufficiency of which are
hereby acknowledged, the parties do hereby agree as follows:

         1.    DePuy shall make its royalty payments pursuant to Section 5.3
of the License Agreement such that Curative will receive approximately 92.3%
of the royalties payable to Cytomedix as follows:

               (i)    Six percent (6%) of any and all net sales made by
sublicensors of Products shall be made directly to Curative, payable on a
quarterly basis by federal funds wire, to the following account of Curative:

                  [Bank Name: Wells Fargo Bank Minnesota
                  Account Name: Curative Health Services, Inc.
                  ABA Number: 091000019
                  Account Number: 49904]; and

               (ii)   One-half percent (0.5%) of any and all net sales made
by sublicensors of Products shall be made to Cytomedix, as set forth in the
License Agreement.

         2.    Curative shall be a direct beneficiary of the royalty payments
set forth in the License Agreement, and as such, shall be entitled to enforce
any rights of Cytomedix relating to the payment of such royalties, as if
Curative had been a party to the License Agreement.

         3.    In order to transfer the interest of Cytomedix in the License
Agreement to another party, DePuy must consent to such transfer as set forth
in Section 13 of the License Agreement. By executing this Agreement, DePuy
hereby consents to such transfer of interest.

                                       5

<PAGE>

                          [SIGNATURE PAGE TO AGREEMENT]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first written above.

                                          CYTOMEDIX:
                                          Cytomedix, Inc.

                                          By:__________________________

                                          Name:
                                          Its:

                                          CURATIVE:
                                          Curative Health Services, Inc.

                                          By:__________________________
                                          Name:
                                          Its:

                                          DEPUY:
                                          DePuy AcroMed, Inc.

                                         By:__________________________
                                         Name:
                                         Its:

                                       6<PAGE>

                    EXTENSION AND NOTE MODIFICATION AGREEMENT

     THIS EXTENSION AND NOTE MODIFICATION AGREEMENT is executed effective this
20th day of April, 2001, by and among Cytomedix, Inc., a Delaware corporation
(the "Company") and BDR, Inc., as agent for undersigned Holders of those certain
10% Convertible Secured Promissory Notes issued by the Company dated as of
December 26, 2000 described on EXHIBIT "A" (the "Holders").

                              W I T N E S S E T H :

     WHEREAS, the Holders have acquired by assignment the interests of Bel-Cap
Delaware, LLC and TSENVI, LLC (the "Initial Lenders") in those certain 10%
Convertible Secured Promissory Notes issued by the Company dated effective as of
December 26, 2000 in the original principal amount of Seven Hundred Thousand
Dollars ($700,000.00) each, or One Million Four Hundred Thousand Dollars
($1,400,000.00) in the aggregate (the "Notes"); and

     WHEREAS, the Holders have now assumed the rights and obligations of the
Initial Lenders by assignment of the Notes and are now the Lenders and Secured
Parties pursuant to that certain Security Agreement dated effective as of
December 26, 2000, by and between the Company, as Debtor, and the Initial
Lenders, as Secured Parties; and

     WHEREAS, the Company desires to extend the term on the payment of the
remaining outstanding balance of the Notes (which is $708,000) and re-borrow an
additional $312,000 on the same terms and conditions and requests that the
Holders subordinate their security interest in the assets of the Company to the
security interest to be granted in favor of the purchasers of the Company's 12%
Convertible Secured Promissory Notes of even date herewith and the Holders are
willing to extend the term and subordinate the security interest on the terms
and conditions set forth herein.

     NOW, THEREFORE, for good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, and the further consideration of the
mutual promises and covenants contained herein, the parties hereto agree as
follows:

     1. EXTENSION OF MATURITY DATE AND ADDITIONAL LOANS. In consideration for
the issuance of the consideration described in Paragraph 3 below, the Holders
hereby agree to extend the maturity date of the Notes from April 15, 2001
through April 15, 2002 and loan the Company an additional $312,000 as evidenced
by an increase in the unpaid balance of the Notes acquired from the Initial
Lenders. As further consideration for the payments described in Paragraph 3
below, all references to the maturity date set forth in the Notes shall be
deemed to mean and refer to April 15, 2002, including, but not limited to, any
maturity dates with respect to defaults, conversion price adjustments, etc.

     2. SUBORDINATION OF SECURITY INTEREST. Holders hereby agree to subordinate
their security interest in the assets of the Company to the security interest to
be created in favor of First Security Bank, as collateral agent, for the benefit
of the purchasers of the

<PAGE>

Company's Series 2001 12% Convertible Promissory Notes. Holders shall execute
and deliver such amendments to the existing UCC Financing Statements as may be
necessary to evidence their express agreement to subordinate the existing
security interest created under the Security Agreement dated as of December 26,
2000.

     3. CONSIDERATION. As consideration for the Holders' extension of the
maturity date, waiver of any existing defaults under the Notes and subordination
of their security interest in favor of First Security Bank, as collateral agent,
the Company shall deliver Warrants representing the right to purchase Three
Hundred Sixty-four Thousand Two Hundred and Eighty-Nine (364,289) shares of the
Company's common stock to the Holders on a pro rata basis in accordance with
their respective interests in the remaining outstanding principal balance of the
Notes as of the date of this Agreement. The Warrants shall have an exercise
price of $.50 per share and shall be exercisable at the option of the Holder and
in the form of that attached hereto as EXHIBIT "B". The shares into which the
Warrants are convertible upon exercise shall be registered in accordance with
the Registration Rights Agreement described in Paragraph 4 below.

     4. REGISTRATION RIGHTS. The Company hereby ratifies and confirms the
registration rights with respect to the shares of common stock into which the
remaining unpaid principal balance of the Notes is convertible pursuant to the
terms of that certain Registration Rights Agreement dated effective as of
December 26, 2000. Furthermore, the Company agrees to execute and deliver an
additional Registration Rights Agreement on substantially the same terms and
conditions as the December 26, 2000 agreement (or an amendment to said
agreement), which would include the shares of common stock to be issued upon the
exercise of the Warrants described in Paragraph 3 above.

     5. WAIVER OF DEFAULTS; ADDITIONAL WAIVERS. The Holders hereby acknowledge
and agree that they waive any existing default under the Notes, Security
Agreement and any other collateral documents between the Company and the Holders
as of the date of this Agreement. Such waiver and release shall be effective on
a one time basis and shall not be deemed or construed to constitute a waiver,
agreement to waive or any other commitment on the part of the Holders with
respect to any defaults arising from and after the date hereof. Additionally,
the Holders waive the requirements or the rights under the Loan Documents: (i)
with respect to the requirement to register and reserve two (2) times the number
of shares that would otherwise be issued in connection with the conversion of
the Notes held by the Holders and the exercise of the Warrants granted hereunder
(the Company only being required to reserve and register the amount of shares
otherwise issuable in connection conversion and exercise thereof); and (ii) to
have one or more representatives to attend or otherwise participate in meetings
of the Company's Board of Directors or to have the right to obtain prior written
copies of all consents in lieu of Board of Directors meetings.

     6. EFFECT ON AGREEMENTS. Except as otherwise specifically set forth and
modified herein or in that certain Consent, Waiver Payoff and Exchange Agreement
dated April 30, 20001, by and among the Company, Curative and the Initial
Lenders, the remaining terms and conditions of the Notes, Security Agreement,
Registration Rights Agreement and other Loan

<PAGE>

Documents (as defined in the Notes) shall remain in full force and effect and
shall not otherwise be modified, amended or revoked.

     7.   MISCELLANEOUS.

          (a) ASSIGNMENT. This Agreement and the rights, obligations and duties
of the Company hereunder shall not be assignable or otherwise transferable by
Company. Any Holder may, upon notice to Company, transfer, participate or assign
any or all of its rights and obligations under this Agreement.

          (b) FEES OF LEGAL COUNSEL. In the event a Holder shall employ legal
counsel to protect its rights hereunder or to enforce any term or provision
hereof, such attorneys' fees and other legal expenses shall become part of the
Secured Debt described in the Security Agreement and shall be payable by Company
to a Holder upon demand.

          (c) FURTHER ASSURANCES. Company agrees that from time to time
hereafter, upon request, it will, at its sole expense, execute, acknowledge and
deliver such other instruments and documents and take such further action as may
be reasonably necessary to carry out the intent of this Agreement and the Loan
Documents.

          (d) MODIFICATION. No term or provision contained herein may be
modified, amended or waived except by written agreement or consent signed by the
party to be bound thereby.

          (e) BINDING EFFECT AND BENEFIT. This Agreement shall inure to the
benefit of, and shall be binding upon, the parties hereto, their heirs,
executors, administrators, personal representatives, successors in interest and
permitted assigns.

          (f) HEADINGS AND CAPTIONS. Subject headings and captions are included
for convenience purposes only and shall not affect the interpretation of this
Agreement.

          (g) NOTICE. All notices, requests, demands and other communications
permitted or required hereunder shall be in writing, and either (i) delivered in
person, (ii) sent by express mail or other overnight delivery service providing
receipt of delivery, (iii) mailed by certified or registered mail, postage
prepaid, return receipt requested or (iv) sent by telex, telegraph or other
facsimile transmission to such other address as either party may designate by
notice in accordance with this Section. Any such notice or communication, if
given or made by prepaid, registered or certified mail or by recorded express
delivery, shall be deemed to have been made when actually received, but not
later than three (3) business days after the same was properly posted or given
to such express delivery service and if made properly by telex, telecopy or
other facsimile transmission such notice or communication shall be deemed to
have been made at the time of dispatch.

          (h) SEVERABILITY. If any portion of this Agreement is held invalid,
illegal or unenforceable, such determination shall not impair the enforceability
of the remaining terms and

<PAGE>

provisions herein, which may remain effective, and to this end this Agreement is
declared to be severable.

          (i) TIME FOR PERFORMANCE. Time is of the essence in this Agreement.

          (j) WAIVER. No waiver of a default, breach or other violation of any
provision of this Agreement shall operate or be construed as a waiver of any
subsequent default, breach or other violation or limit or restrict any right or
remedy otherwise available. No delay or omission on the part of any Holder or
Collateral Agent to exercise any right or power arising by reason of a default
shall impair any such right or power or prevent its exercise at any time during
the continuance thereof.

          (k) GENDER AND PRONOUNS. Throughout this Agreement, the masculine
shall include the feminine and neuter and the singular shall include the plural
and vice versa as the context requires.

          (l) ENTIRE AGREEMENT. This Agreement and each Note constitute the
entire agreement of the parties and supersedes any and all other prior
agreements, oral or written, with respect to the subject matter contained
herein.

          (m) GOVERNING LAW; WAIVER OF JURY TRIAL. THIS AGREEMENT SHALL BE
INTER-PRETED, AND THE RIGHTS AND LIABILITIES OF THE PARTIES HERETO DETERMINED,
IN ACCORDANCE WITH THE INTERNAL LAWS (AS OPPOSED TO CONFLICTS OF LAW PROVISIONS)
OF THE STATE OF ILLINOIS. AS PART OF THE CONSIDERATION FOR NEW VALUE THIS DAY
RECEIVED, THE DEBTOR HEREBY CONSENTS TO THE JURISDICTION OF ANY STATE OR FEDERAL
COURT LOCATED WITHIN CHICAGO, STATE OF ILLINOIS. EACH OF THE PARTIES HEREBY
IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY SUIT OR PROCEEDING
ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE OTHER LOAN DOCUMENTS. THE
DEBTOR WAIVES ANY OBJECTION WHICH THE DEBTOR MAY HAVE BASED ON LACK OF
JURISDICTION OR IMPROPER VENUE OR FORUM NON CONVENIENS TO ANY SUIT OR PROCEEDING
INSTITUTED BY ANY LENDER OR COLLATERAL AGENT UNDER THIS AGREEMENT OR THE OTHER
LOAN DOCUMENTS IN ANY STATE OR FEDERAL COURT LOCATED WITHIN CHICAGO, STATE OF
ILLINOIS AND CONSENTS TO THE GRANTING OF SUCH LEGAL OR EQUITABLE RELIEF AS IS
DEEMED APPROPRIATE BY THE COURT. NOTHING IN THIS SECTION SHALL AFFECT THE RIGHT
OF ANY LENDER OR COLLATERAL AGENT TO BRING ANY ACTION OR PROCEED-ING AGAINST THE
DEBTOR OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDIC-TION WHICH HAS
JURISDICTION OVER THE DEBTOR OR ITS PROPERTY. THIS PROVISION IS A MATERIAL
INDUCE-MENT FOR THE LENDERS AND COLLATERAL AGENT TO ENTER INTO THIS AGREEMENT
AND THE OTHER LOAN DOCUMENTS, MAKE THE LOANS AND EXTEND THE OTHER FINANCIAL
ACCOMMODA-TIONS CONTEM-PLATED HEREUNDER AND THEREUNDER.

<PAGE>

          (n) COUNTERPARTS. This Agreement may be executed in one or more
counterparts (all counterparts together reflecting the signature of all parties)
each of which shall be deemed an original, and all of which together shall
constitute one and the same instrument.

          (o) SURVIVAL OF AGREEMENTS. All agreements, covenants, representations
and warranties contained herein or made in writing by or on behalf of the
Company in connection with the transactions contemplated hereby shall survive
the execution and delivery of this Agreement and the other Loan Documents.

     IN WITNESS WHEREOF, this Extension and Note Modification Agreement is
executed effective the day and year first above written.

                                       CYTOMEDIX, INC.

                                       By:  /s/ James A. Cour

                                       Title: President and Chief Executive
                                              Officer

                                       HOLDERS:

                                       BDR, Inc.
                                       As Agent

                                       By: /s/ Jim D. Swink
                                           Jim D. Swink, Jr., President

<PAGE>

                                   EXHIBIT "A"

                                     HOLDERS
<TABLE>
<CAPTION>
NAME                                                  PRO RATA PERCENTAGE
--------------------------------------------------------------------------------
<S>                                                           <C>
John Steed                                                    5.39%
David Crews                                                   12.25%
Mike Grady                                                    2.45%
Scott Naurath                                                 2.45%
Pete Tindell                                                  2.45%
Alfred Jordan                                                 2.45%
Clark Raborn                                                  0.98%
Don Walker Barrett, III Trust                                 2.45%
David Davis Barrett Trust                                     2.45%
Stephen Chaffin                                               2.45%
Steve Selakovich                                              2.45%
 Lana Crews                                                   2.45%
Glenn Smith                                                   4.41%
Blake Murchison                                               12.25%
Bart Barnwell                                                 8.33%
David Alexander                                               7.35%
Rush F. Harding III                                           4.90%
BDR, Inc.                                                     9.80%
Lewis Pollack                                                 4.90%
Tim Mariani                                                   0.98%
Price C. Gardner                                              0.78%
Dalton A. Farmer, Jr.                                         0.49%
J. Lee Brown                                                  0.49%
Christopher J. Heller                                         1.18%
Regions Bank, Trustee Friday, Eldredge & Clark
401k Plan fbo Christopher J. Heller                           1.47%
L&L Investments, Ltd                                          1.47%
H.E. Cummins                                                  0.49%

Total                                                          100%
</TABLE>

<PAGE>

                                   EXHIBIT "B"

                                 FORM OF WARRANT

<PAGE>

                                   EXHIBIT "C"

                          REGISTRATION RIGHTS AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}]]